Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

249
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
249
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

241
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
241
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

224
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
224
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

356
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
356

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

The Evolving Role of Eosinophils in Eosinophilic Esophagitis: Mechanisms, Crosstalk, and Therapeutic Perspectives.

Cells·2026
Same author

Fibrotic chronic eosinophilic pneumonia: from inflammation to fibrosis and therapeutic implications.

European respiratory review : an official journal of the European Respiratory Society·2026
Same author

Switching Biologics in Severe Asthma: Cautionary Lessons from NIMBLE.

American journal of respiratory and critical care medicine·2026
Same author

Remission in Global Airway Diseases: EUFOREA Consensus Paper.

Allergy·2026
Same author

Anaphylaxis and Epinephrine Use in Pregnancy.

The journal of allergy and clinical immunology. In practice·2026
Same author

Efficacy and safety of tezepelumab versus placebo in reducing oral corticosteroid use in adults with severe, oral corticosteroid-dependent asthma (SUNRISE): a multicentre, placebo-controlled, double-blind, phase 3 trial.

The Lancet. Respiratory medicine·2026

相关实验视频

Updated: Jun 11, 2025

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

31.9K

治疗严重喘的Tezepelumab:提升当前的做法,以识别表皮驱动的配置文件.

Marco Caminati1,2, A Vatrella3, P Rogliani4

  • 1Allergy Unit and Asthma Center, Integrated University Hospital of Verona, Verona, Italy. marco.caminati@univr.it.

Respiratory research
|October 9, 2024
PubMed
概括

采佩卢马布通过向上皮功能障碍有效治疗喘,通过功能生物标志物 (如呼吸道过敏反应) 识别最适合的患者. 这种方法提升了个性化医疗,超越了传统的喘表型.

关键词:
生物标志物 生物标志物皮质屏障是一种表皮屏障.现型化 (Phenotyping) 是一种表现方式.严重的喘 严重的喘泰泽佩卢姆巴布 (Tezepelumab) 是一个小镇.

更多相关视频

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis
03:23

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis

Published on: May 10, 2024

678
Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
10:39

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

7.6K

相关实验视频

Last Updated: Jun 11, 2025

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

31.9K
Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis
03:23

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis

Published on: May 10, 2024

678
Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
10:39

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

7.6K

科学领域:

  • 肺部医学 肺部医学
  • 免疫学 免疫学 免疫学
  • 皮质生物学 皮质生物学

背景情况:

  • 表皮功能障碍越来越多地被认为是喘病因.
  • 一种针对TSLP的生物药物Tezepelumab在喘患者中显示出广泛的疗效.
  • 确定特定的患者个人资料对于优化tezepelumab使用至关重要.

研究的目的:

  • 为了定义tezepelumab治疗的最佳患者概况.
  • 为了识别表皮驱动喘的特征.
  • 审查关于tzepelumab机制和疗效的证据.

主要方法:

  • 综述已公布的关于tzepelumab的作用机制和临床疗效的数据.
  • 对与表皮屏障功能障碍相关的潜在生物标志物的分析.
  • 环境暴露与喘恶化和治疗反应的相关性.

主要成果:

  • 表皮屏障功能障碍与环境暴露,感染和恶化有关.
  • 佩鲁马布可以减少过敏原和呼吸系统疾病引发的恶化.
  • 功能性生物标志物,如气道过敏反应和支气管可逆性,表明了对tzepelumab的反应.

结论:

  • 功能生物标志物与炎症标志物一起,使得更全面的喘表型化成为可能.
  • 这种方法超越了像T2高或T2低喘这样的限制性标签.
  • 精确的表型优化为符合tezepelumab资格的患者提供个性化医疗.